Keros Therapeutics, Inc.
Financials
Valuation Metrics
Keros Therapeutics, Inc.'s Market Cap is $221M. At end of 2025 it was $758M. Ranked #3004 of 3,121 in US market (top 96%), #1371 of 1,463 on NASDAQ (top 94%), #249 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $221M | US#3,004/3,121 Sec#249/266 |
| Revenue | $15M | US#2,823/3,121 Sec#167/266 |
| Net Income | $-83M | US—/3,121 Sec—/266 |
| Total Assets | $288M | US#2,921/3,121 Sec#212/266 |
| Net Assets | $262M | US#2,582/3,121 Sec#165/266 |
| Employees | 92 | US#2,645/3,121 Sec#185/266 |
| Value | ||
| P/B | 0.84x | US#264/3,121 Sec#8/266 |
| P/S | 14.75x | US#2,792/3,121 Sec#132/266 |
| FCF Yield | -21.89% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -31.70% | US#2,578/3,121 Sec#115/266 |
| ROA | -28.91% | US#2,873/3,121 Sec#151/266 |
| Op. Margin | -675.82% | US#2,816/3,121 Sec#160/266 |
| Revenue Growth | -93.55% | US#2,770/3,121 Sec#183/266 |
| Earnings Growth | -542.97% | US#2,012/3,121 Sec#68/266 |
| Financial Health | ||
| Debt Ratio | 9.64% | US#107/3,121 Sec#50/266 |
| Total Debt | $16M | US#2,791/3,121 Sec#195/266 |
| FCF | $-48M | US#2,525/3,121 Sec#113/266 |
| Cash | $258M | US#1,543/3,121 Sec#92/266 |
| Current Ratio | 21.96x | US#109/3,121 Sec#20/266 |
| Performance | ||
| 1Y Return | -30.24% | US#2,569/3,121 Sec#222/266 |
| 1M Return | 0.81% | US#353/3,121 Sec#39/266 |
| From 52W High | -50.38% | US#2,717/3,121 Sec#213/266 |
| 1Y MDD | -54.62% | US#2,620/3,121 Sec#197/266 |
| Trading | ||
| Volume | 235,574 shares | US#2,474/3,121 Sec#239/266 |
| Trading Value | $3M | US#2,806/3,121 Sec#240/266 |
| Per Share | ||
| EPS | $-4.20 | US—/3,121 Sec—/266 |
| BPS | $13.25 | US#1,631/3,121 Sec#52/266 |
Company Info
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.